Independent provider comparison
Updated September 27, 2026
A side-by-side look at total cost, medication format, care, commitment and the situations where each option makes more sense.
Embody’s GLP-1 website is joinem.co. GLP-1 Picks is an independent comparison site.
The short decision
Embody is our starting recommendation for a cash-paying reader who wants a compounded injection and a clearly priced one-month option. Its public semaglutide catalogue plan is $79 with medication included. MEDVi is worth exploring when treatment format matters more: it lists oral and injectable routes. Our choice comes down to the prescribed product, the ongoing bill and the care you want. The detailed sections below explain MEDVi's dated price and regulatory records so you can make that choice with context.
Both providers pay us a commission through our links. Our recommendation reflects the needs described here; commissions do not set scores. How we make money.
Our pick for a simple cash-pay injection plan
Medication, clinical review, coaching and shipping in one plan. Start with one month if you want a smaller initial commitment.
Semaglutide: $79 for one month, or $828 prepaid for a year ($69/month equivalent). Compounded treatment requires clinical approval and is not FDA approved.
Explore Embody's plans Read our Embody review
Choose MEDVi to explore more treatment formats
MEDVi lists injection and oral treatment routes. It is worth comparing if the way you take medication is central to your decision.
Compare the prescribed product and ongoing total. Compounded tablets are not FDA-approved pills; the dated regulatory record is explained below.
Explore MEDVi's options Read our MEDVi reviewSources: Embody catalogue and payment terms · Medvi program
Cost
First charge, renewal and commitment
Treatment
Medication, form and approval status
Care
Clinical review and ongoing support
Terms
Cancellation and material cautions
Side by side
Compare the price unit as well as the number. A medication-only price, prepaid monthly equivalent and complete recurring program are not the same thing.
| Feature | Embody | MEDVi |
|---|---|---|
| Why each one | Publishes a complete four-tier price ladder for both molecules, so the commitment behind every advertised rate is checkable rather than implied. | A daily dissolvable GLP-1 tablet and a weekly compounded injection in one program, plus brand-name Wegovy and Zepbound on a $99 membership. |
| Our Score | 7.3/10 | 5.7/10 |
| Headline Price | from $69/mo | $179 first month, then $299/mo |
| Medication Type | Compounded | Both |
| Insurance Accepted | No | No |
| Best For | People who want to compare Embody's published plan menu with its separate monthly promotion and will confirm the exact charge, term and refund rules before paying | Users who want both oral and injectable compounded options in one telehealth program |
| Watch out for | Payments are normally non-refundable. If Embody's provider determines medical disqualification, its refund policy allows a refund for unused services after deducting services already provided. Cancellation otherwise stops future renewal. The twelve-month semaglutide plan commits $828 up front; cancellation requests must reach support at least 72 hours before the next billing date. | FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication |
| Ranking | #17 | #25 |
| Get started | Visit Embody | Visit MEDVi |
For Embody's one-month prices, prepaid totals and conflicting billing terms, read the Embody price and payment breakdown.
Trade-offs
Embody's public catalogue lists compounded semaglutide at $79 for one month and tirzepatide at $129, with lower monthly equivalents on longer prepaid terms. A separate promotional landing advertises $69/$119 flat monthly and says its month-to-month option has no contract; its final checkout charge was not verified on September 20. Our September 3 check of MEDVi's linked offer recorded compounded semaglutide at $179 for month one and $299 for refills. Embody publishes the lower floor on these snapshots, but a defensible comparison requires the exact medication, first charge and term at checkout.
The trade-off is choice. Embody's September 3 catalogue lists compounded semaglutide and tirzepatide injections; its former oral tirzepatide gum is absent. MEDVi lists compounded semaglutide injections and dissolvable tablets, plus separate brand-name routes. Its Zepbound injection is brand-name tirzepatide, not compounded tirzepatide. The landing lists a $99 membership plus medication for Zepbound, with availability subject to change; that is not a complete treatment price.
Sources: Embody published product catalogue · Current MEDVi offer (affiliate link) · MEDVi injection costs and pharmacy details
MEDVi offers more ways to take treatment. It lists oral tablets and injections for compounded GLP-1 care, while Embody's September 3 catalogue lists injections only; its former tirzepatide gum is absent. Both now name pharmacy partners: MEDVi lists RedRock Pharmacy, Beaker Pharmacy & Compounding and Triad Rx; Embody lists Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx.
The dated Trustpilot readings differ: MEDVi showed 4.3/5 across 14,680 reviews on September 3, 2026, while Embody showed 3.8/5 across 8,121 on September 20. Embody's profile includes merged reviews. Do not treat either rating as clinical-quality evidence. MEDVi had an unaccredited F rating at the BBB on our prior check. Embody's shared operator showed C, not accredited, with 72 complaints company-wide on September 22; the profile also lists SnagRx and RodeoMeds as alternate names.
Sources: MEDVi on Trustpilot · MEDVi pharmacy terms · MEDVi at the BBB · Embody on Trustpilot
The FDA issued warning letter #721455 to MEDVi on February 20, 2026. The agency says MEDVi-branded labels implied MEDVi compounded the products when it did not, and that website comparisons implied compounded semaglutide and tirzepatide were equivalent to or FDA-evaluated like approved brands. This is a misbranding and marketing action, not an allegation that the medication was unsafe.
Our published rubric applies the same 2.0-point penalty when an FDA warning letter has no public close-out record. No public close-out letter for MEDVi was found as of August 14, 2026, so MEDVi moves from its 7.7 base score to 5.7. MEDVi gets no scoring exception because it is an affiliate partner.
Sources: FDA warning letter #721455 · Our scoring methodology
Embody publishes the lower starting rates: compounded injections from $69/mo and GLP-1 + GIP injections from $129/mo, compared with MEDVi's $179 semaglutide first month and $299 refills. Embody ties its advertised rates to a selected plan length, so compare the exact medication and commitment at checkout rather than treating either floor as a universal annual total.
On our separate dated checks, MEDVi showed 4.3/5 across 14,680 Trustpilot reviews on September 3, 2026, and Embody showed 3.8/5 across 8,121 on September 20. Embody's profile includes merged reviews. MEDVi had an F, non-accredited BBB profile on our prior check; Embody's shared operator showed C, not accredited, with 72 complaints company-wide on September 22. The review and complaint signals are mixed rather than clean endorsements.
We cannot prove one provider's medication is safer from public records alone. We can compare the regulatory and disclosure record: MEDVi received FDA warning letter #721455 for misleading labeling and marketing, while no FDA warning letter is recorded for Embody in our current safety database. The MEDVi letter does not allege unsafe medication. MEDVi names three pharmacy partners and Embody names four; neither disclosure proves medication quality by itself.
Consider Embody first if the lower advertised plan rate fits your medication and commitment. Consider MEDVi if you specifically need its oral tablet formats or brand-name paths and are comfortable with the $179-to-$299 price step, BBB F and FDA warning record. Both pay us a commission, so affiliate status does not break the tie.
Keep narrowing the decision
Use the unresolved part of this choice, not a generic related article. These guides own the broader medication, coverage or complete-cost question.
More head-to-head comparisons involving Embody and MEDVi.
Not comparing, just asking? Quick answers to the most-asked GLP-1 questions →
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.
Still working out whether either one is above board? We check that separately: is Embody legit and is MEDVi legit, with the verification evidence behind each answer.
